GD2 and GD3 gangliosides as prognostic biomarkers in high grade serous ovarian cancer - 03/10/24

Doi : 10.1016/j.jogoh.2024.102860

Gabriel Levin ^1,^⁎ , Emad Matanes ¹, Amber Yasmeen ², Raanan Meyer ³, Melica Nourmoussavi Brodeur ¹, Shannon Salvador ¹, Susie Lau ¹, H. Uri Saragovi ^2,⁴, Walter Gotlieb ¹
¹ Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada
² Segal Cancer Center, Lady Davis Institute of Medical Research, McGill University, Montreal, Quebec, Canada
³ Division of Minimally Invasive Gynecologic Surgery, Department of Obstetrics and Gynecology, Cedars Sinai Medical Center, Los Angeles, California, USA
⁴ Pharmacology and Therapeutics, McGill University, Montreal, QC, Canada

^⁎Corresponding author: Gabriel Levin, MD, Division of Gynecologic Oncology, Jewish General Hospital, McGill University, Montreal, Quebec, Canada, Lab: (+1) 514 3408222 ext. 22979. Mobile: (+1) 514-6495785.Division of Gynecologic OncologyJewish General Hospital, McGill UniversityMontrealQuebecCanada

Sous presse. Manuscrit accepté. Disponible en ligne depuis le Thursday 03 October 2024
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder

Abstract

Objective

Gangliosides GD2 and GD3 have been proposed to be of significance in diagnosis of ovarian masses. We aim to study serum GD2 and GD3 gangliosides as predictors of oncological outcomes among high grade serous (HGS) ovarian cancer (OC).

Materials and methods

A retrospective study including biobanked serum samples of HGS OC treated between 2005-2016. Serum GD2 and GD3 concentrations were quantified using indirect ELISA and analyzed with respect to survival.

Results

Sixty patients were included. Patients with GD3>12.8ng/mL had shorter PFS when compared to patients with lower level; median 31 vs. 67 months, p =.005. Patients with GD2> 7.1ng/mL had shorter median PFS than those with lower level of (23 vs. 52 months, p =.024.) Patients with GD3>14.5ng/mL had shorter OS vs. patients with lower level (median 31 vs. 70 months, p =.002). In a Cox regression, following adjustment for age, CA-125, disease stage and age, serum elevated GD3 was independently associated with short PFS (adjusted hazard ratio 2.0, 95% CI 1.1-3.8, p=.024). In a separate Cox regression, elevated GD2 was independently associated with PFS (adjusted hazard ratio3.0 (1.2-7.7). p=.019. High serum GD3 and GD2 were independently associated with short OS as well.